Upharmacia - April 2016

Ukrainian Pharmaceutical Market Monthly
Upharmacia
Macroeconomic Environment | Market & Companies News |
Regulatory Updates | Healthcare News
Issue: 04 2016
UPharma Consulting is a professional consulting company, operating in the Life Sciences sector. We deliver
best global practices in market knowledge, people management, marketing and strategy in the CIS/CEE.
UPharma Consulting
Kiev / www.upharma-c.com / mailbox@upharma-c.com / +380 (44) 232-11-42

Ukrainian Pharmaceutical Market Monthly: April 2016
2015 2016
Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar
MACROECONOMIC INDICATORS
Q2 Q3 Q4 Q1
GDP (US$ bn) 20.795 25.552 25.588
growth, % y-o-y -35% -26% -17%
Export of Goods (US$ bn) 3.45 3.07 2.94 3.09 3.15 3.09 3.35 3.23 3.13 3.36 2.04 3.08 2.99
growth, % y-o-y -32% -39% -41% -30% -34% -22% -22% -23% -21% -11% -31% 3% -13%
Import of Goods (US$ bn) 3.17 2.86 2.63 2.76 2.98 3.88 3.24 3.22 3.07 3.12 2.23 2.68 3.35
growth, % y-o-y -35% -38% -46% -37% -34% -2% -30% - 27% -27% -32% -26% -6% 5%
Industrial Production Sales (US$ bn) 5.51 5.91 5.65 5.79 5.71 5.42 5.72 6.29 5.92 6.37 4.93 4.93 5.41
growth, % y-o-y -45% -33% -38% -35% -33% -23% -20% -21% -19% -17% -18% 8% -2%
Retail Turnover of Enterprises (US$ bn) 1.61 1.66 1.94 1.83 1.94 1.88 1.86 2.04 1.80 2.01 1.60 1.50 1.64
growth, % y-o-y -56% -40% -35% -38% -41% -32% -38% -31% -33% -29% -19% 4% 2%
Unemployment Rate (%) 1.9 1.8 1.8 1.7 1.6 1.6 1.5 1.5 1.6 1.9 1.9 1.9 1.7
Average Salary (US$) 166 176 193 202 202 194 199 207 193 223 180 174 187
OFFICIAL CURRENCY EXCHANGE RATE
UAH / USD 23.3 22.7 20.9 21.2 21.8 21.6 21.8 21.8 23.3 23.4 24.3 26.4 26.4
UAH / EUR 25.3 24.5 23.3 23.8 23.9 24.0 24.5 24.6 25.1 25.4 26.3 29.3 29.2
PHARMACEUTI CAL INDUSTRY INDICATORS
Export of Pharma Products (mio USD) 13.37 13.46 13.00 15.36 13.85 9.01 13.79 12.2 11.7 15.77 8.31 13.33 15.54
growth, % y-o-y -50% -44% -39% -39% -6% -54% -47% -37% -52% -28% -30% 11% 16%
Import of Pharma Products (mio USD) 103.3 103.7 84.2 115.0 106.5 93.3 121.1 147.1 141.3 142.1 103.7 145.0 125.1
growth, % y-o-y -67% -36% -60% -44% -47% -47% -31% -28% -24% -42% 15% 27% 21%
Pharma Retail Sales, values (mio USD) 197.6 180.0 193.0 177.7 172.6 177.1 193.2 206.3 196.6 212.3 198.9 176.0 187.3
growth, % y-o-y -47% -40% -28% -29% -32% -24% -28% -26% -20% -18% -17% -1% -5%
Pharma Retail Sales, volumes (mio units) 141.5 122.6 124.5 118.4 119.5 122.5 126.7 130.2 129.0 136.4 133.6 126.8 133.8
growth, % y-o-y -21% -20% -11% -9% -10% -8% -11% -5% -4% -5% 1% -12% -5%
WACP (USD) 1.24 1.41 1.47 1.52 1.48 1.45 1.52 1.58 1.52 1.56 1.49 1.39 1.40
growth, % y-o-y -40% -27% -23% -21% -23% -18% -19% -22% -18% -14% -23% -23% 13%
CPI of Ukraine 145.8 160.9 158.4 157.5 155.3 152.8 151.9 146.4 138.1 134.6 131.9 126.9 113.5
Pharmaceutical Products CPI 170.3 164.7 159.5 153.5 151.8 149.4 145.8 142.1 146.6 143.3 140.3 132.7 120.9
Local Companies share, values (%) 39.6 40.7 41.5 41.7 41.8 41.4 41.4 41.4 41.7 40.9 42.3 42.9 42.7
Local Companies share, volumes (%) 77.1 77.6 77.6 77.9 78.4 78.2 76.5 75.7 75.8 76.7 75.6 76.5 76.5
MACROECONOMIC ENVIRONMENT
Description of the indicators:
MACROECONOMIC INDICATORS
GDP (Gross Domestic Product) is an aggregate measure of production equal to the sum of the
gross values added of all resident, institutional units engaged in production (plus any taxes, and
minus any subsidies, on products not included in the value of their outputs) calculated in current
prices. Converted from UAH to USD in accordance with an average official NBU exchange
rate in the corresponding period. Hereinafter: excluding the temporarily occupied territory of
the Autonomous Republic of Crimea and City of Sevastopol, as well as the part of zone of the
antiterrorist operation. Source: State Statistics Service of Ukraine.
Export of Goods is a sale of goods by Ukrainian subjects of foreign economic activities to foreign
subjects of foreign economic activities (including non-cash payment) with or without exportation
of these goods through the customs border of Ukraine, including the re-export of goods. Initially
calculated in USD. Source: State Statistics Service of Ukraine.
Import of Goods is a purchase (including non-cash payment) of goods by Ukrainian subjects
of foreign economic activities in foreign subjects of economic activities with or without the
importation of these goods into the territory of Ukraine, including the purchase of goods for
domestic consumption by establishments and organizations of Ukraine located abroad. Initially
calculated in USD. Source: State Statistics Service of Ukraine.
Industrial Production Sales is the value of industrial goods, which are actually shipped in the
period, as indicated in documents decorated as the basis for calculating with the buyer (customer),
regardless of income payments for them. Converted from UAH to USD in accordance with an
average official NBU exchange rate in the corresponding period. Source: State Statistics Service
of Ukraine.
Retail Turnover of Enterprises is the value of consumer goods sold via retail trade and
restaurants to the population by all operating enterprises. It also includes direct retail sales by
industrial, transport and other non-trade enterprises. In addition, retail turnover includes retail
sales of food products to departments, organizations and enterprises to provide meals to the
people they serve (at sanatoria, children’s care institutions, hospitals, etc.). Reflected in current
prices. Converted from UAH to USD in accordance with an average official NBU exchange rate in
the corresponding period. Source: State Statistics Service of Ukraine.
Unemployment Rate is a ratio (percent) of the unemployed registered at the State Employment
Service to the average annual population of working age. Source: State Statistics Service of
Ukraine.
Average Salary is an average value of remuneration in cash and in kind paid to employees for
time worked or work done. Converted from UAH to USD in accordance with an average official
NBU exchange rate in the corresponding period. Source: State Statistics Service of Ukraine.
Official Currency Exchange Rate is the rate established by the National Bank of Ukraine
under which Ukrainian national currency – UAH (Ukrainian hryvnia) will be exchanged for foreign
currency (USD or EUR). Calculated as average value in the corresponding period. Source: National
Bank of Ukraine.
PHARMACEUTICAL INDUSTRY INDICATORS
Export of Pharma Products is an export of goods related to the group “Pharmaceutical products”
under the Ukrainian Classification of Goods for Foreign Economic Activities. Initially calculated in
USD. Source: State Statistics Service of Ukraine.
Import of Pharma Products is an import of goods related to the group “Pharmaceutical products”
under the Ukrainian Classification of Goods for Foreign Economic Activities. Initially calculated in
USD. Source: State Statistics Service of Ukraine.
Pharma Retail Sales are retail sales of different product categories of “pharmacy basket” (drugs,
medical devices, cosmetics and food supplements) in values and volumes. Converted from UAH
to USD in accordance with an average official NBU exchange rate in the corresponding period.
Source: Morion.
WACP (Weighted average cost of a pack) is a ratio of pharma retail sales in values to pharma
retail sales in volumes.
CPI (Consumer price index) is an indicator of changes at the time of prices and tariffs for
commodities and services being purchased by the population for unproductive consumption
calculated to corresponding month of previous year. Source: State Statistics Service of Ukraine.
Pharma Products CPI is a Consumer price index of “Pharmaceutical products, medical products,
appliances and equipment” group calculated to corresponding month of previous year. Source:
State Statistics Service of Ukraine.
Local Companies Share is the share (percent) of sales related to Ukrainian companies in overall
pharma retail sales in values and volumes. Source: Morion
Table: Key Macroeconomic
Indicators in Ukraine
(Mar 2015-Mar 2016)

KEY ECONOMIC EVENTS
»» On Apr 15, Ukrainian Parliament formed a new coalition and approved new Cabinet of Ministers, endeavoring of
resolve the political crisis in Ukraine. Arseniy Yatsenyuk was replaced by Volodymyr Groysman at the position of
Ukraine’s prime minister. Mr. Groysman called corruption, ineffective state administration, and populism as the
key threats for Ukraine right now to fight against.
»» On April 6, 64% of citizens of the Netherlands voted for rejection of ratification of the Ukraine-EU Association
Agreement at the national referendum. However, pro-West politicians and experts believe the poll results will not
affect implementation of Ukraine-EU Association Agreement.
»» In 1Q2016, consumer inflation in Ukraine amounted 1.6%, which was 2.4% lower than National Bank had
forecasted. The Bank sees the probability that in 2016 inflation would be less than 12% estimate, however in Q1
inflation decline was mainly caused by short-term factors.
»» Ukrainian President Petro Poroshenko and U.S. Vice President Joseph Biden agreed to sign the agreement on
the third tranche of loan guarantees for USD 1 bn.
»» The Japanese government has promised USD 1.85 bn in support for the Ukrainian government if it makes
progress on reforms.
»» To receive the next tranche from the IMF, Ukraine will need to adopt 19 Draft Laws, the Deputy Head of the
Presidential Administration said. Ukrainian government expects to receive the tranche of USD 1.7 bn by the
end of 2Q2016.
»» In 2012-2015, trade between Ukraine and Russia fell by USD 98 bn due to deterioration of political relations
and introduction of trade restrictions. The share of exports to Russia in overall exports decreased from 24.3%
in 2012 to 12.7% in 2015.
»» In Mar, Ukraine’s industry continued to recover. Industrial output increased by 4.8% y-o-y compared to 7.6%
y-o-y in Feb. Industries of Donetsk and Lugansk regions have grown significantly – 10.1% and 174% y-o-y. In
3Q2016, industry increased by 3.7% y-o-y.
197.6
180.0
193.0
177.7
172.6
177.1
193.2
206.3
196.6
212.3
198.9
176.0
187.3
141.5
122.6 124.5
118.4
119.5
122.5
126.7
130.2
129.0
136.4
133.6
126.8 133.8
100
110
120
130
140
150
160
100
120
140
160
180
200
220
Pharma Retail Sales
2015 2016
Volumes (mio units)
Values (mio USD)
13.4 13.5
13.0
15.4
13.9
9.0
13.8
12.2
11.7
15.8
8.3
13.3
15.5
103.4 103.7
84.3
115.0
106.6
93.3
122.2
147.1
141.3
142.1
103.7
145.0
125.1
0
20
40
60
80
100
120
140
160
0
4
8
12
16
20
24
Ukraine's International Trade
in Pharma Production
2015 2016
Export
Import
5.51
5.91
5.65
5.80 5.71
5.43
5.72
6.29
5.92
6.37
4.93 4.93
5.41
1.61
1.66
1.94
1.83
1.94
1.88 1.86
2.04
1.80
2.01
1.60
1.50
1.64
0.0
0.5
1.0
1.5
2.0
2.5
3.0
0
1
2
3
4
5
6
7
Industrial Production Sales &
Retail Turnover of Enterprises Surplus
2015 2016
Retail turnover of enterprises
Industrial producƟon sales
23.3 22.7
20.9 21.2 21.8 21.6 21.8 21.8
23.3 23.4 24.3
26.4 26.4
29.5
26.9
25.5 24.9
26.1 25.9 26.1
24.6 25.1 25.4
26.3
29.3 29.2
145.8
160.9 158.4 157.5 155.3 152.8 151.9
146.4 146.6 143.3 140.3
132.7
120.9
0
20
40
60
80
100
120
140
160
0
5
10
15
20
25
30
35
40
45
2015 2016
vs. Consumer Price Index
Official Currency Exchange Rates
CPI of Ukraine
UAH / €
UAH / $

RECRUITING &
EXECUTIVE
SEARCH
We recruit pharma people in the
CIS region and focus on:
> Sales & Marketing
> Regulatory Affairs
> Quality Assurance
> Finances
> Operations
> Administration
We aim to be your trusted advisor
in People Management
Anastasiya MAXIMENKO
Partner, HR-Consulting
AMaximenko@upharma-c.com
+380 (44) 232-11-43
+380 (97) 953-68-14

MARKET & COMPANIES NEWS
German company will
open manufacturing of
medical consumables in
Ukraine
German company Vogt Medical
Vertrieb GmbH intends to open
a plan for the manufacturing of
medical consumables in Cherkasy.
The plans of German investors
were highly endorsed by local
authorities and the MoH.
“This is going to be a unique
manufacturing for our country, as
currently we have to import these
products,” the Head of Cherkasy
Region State Administration Yuri
Tkachenko said.
Vogt Medical have been operating
on the international market of
medical products and medical
consumables for the last 20
years.
“We have chosen Cherkasy
due to convenient logistics and
loyalty of the local government to
investors,” the General Director
of Vogt Medical Michael Fogt
stated. “We plan manufacturing
of consumable materials for
infusion therapy, anesthesiology,
gynecology, dentistry and clinical
products. The project is to be
implemented in a year.”
Galychpharm
developed new
facilities to
produce infusions
Galychpharm company (a
part of Arterium Corporation)
has launched line on the
manufacturing of infusion
solutions. The company received
the corresponding license in Dec
2015.
Earlier, Arterium produced
infusions on a contract basis,
and now the company intends
to strengthen its positions in
hospital segment and take a
significant share of the local
infusions market.
The new production line is
equipped with depyrogenation
tunnel, where glass bottles
are sterilized with hot air at
a temperature of 250 C; this
ensures a high quality of sterile
intravenous preparations.
GSK Ukraine
reports
changes in top-
management
On Apr 1, Alena Likhavets
was appointed to the position
of General Director of GSK
Pharmaceuticals Ukraine,
Belarus, Moldova. Previously, GSK
Pharmaceuticals Ukraine was
managed by Serkan Yagcioglu,
who used to be the GM of GSK
Pharmaceuticals Ukraine, Belarus,
Moldova, Armenia. Currently,
Mr. Yagcioglu is the Head of CIS
cluster of the company. Mrs.
Likhavets previously managed
GSK’s representative office in
Belarus.
Moreover, on 01/04/2016,
Rauno Pukonen was appointed
as General Director of GSK
Consumer Healthcare Ukraine
and CIS. Previously, Mr. Pukonen
was the regional manager of
GSK Consumer Healthcare in the
Baltic States.
GSK in Ukraine is represented by
two units – GSK Pharmaceuticals
and GSK Consumer Healthcare.
Farmak launches
new drug against
influenza
Ukraine’s pharmaceutical market
leader Farmak launched Aydrink®
(paracetamol+phenylephrine)
for the treatment of acute
respiratory infections and
influenza. The drug is produced
in the form of sachets for the
solution. The drug contains the
optimal dose of paracetamol,
which relieves symptoms of colds,
and phenylephrine, which helps
eliminate nasal congestion and
runny nose. The drug does not
cause drowsiness.
In 2015, Farmak increased its
net profit to UAH 407.3 mio.
Drugs for the respiratory system
have the biggest share in the
company’s sales.
EBRD considering
providing funds to
4-5 pharmaceutical
companies
The European Bank for
Reconstruction and Development
(EBRD) is working with four or five
local pharmaceutical companies in
Ukraine, considering the provision
them with funds to implement
their investment plans, the
Senior Banker of the EBRD Iryna
Marchenko said.
“A company should have a clear
investment program, and it is to
suit a long-term strategy of the
enterprise,” Mrs. Marchenko said.
EBRD is also looking for
cooperation with international
companies that have bought a
business in Ukraine. Moreover,
EBRD is interested in supporting
state enterprises, which have
been privatized.
EBRD has successful experience
of cooperation with Farmak and
Sperko companies, as well as
pharmaceutical distributor Venta.
Darnitsa’s
Tivomaks was
most selling launch
in 2015
According to Proxima Research,
Tivomaks (arginine hydrochloride,
Darnitsa) against atherosclerosis,
angiopathy, coronary heart
disease, etc. was the best-selling
brand among ones, which were

launched onto Ukrainian market in
2015. The brand was followed by
Farmak’s anti-inflammatory and
analgesic injection for infusions
Keyver (dexketoprofen) and
Ananta Medicare’s antibacterial
preparation Levacept
(levofloxacin).
Totally, in 2015, 83 companies
have launched 175 new brands
in Ukraine. Overall sales of new
brand amounted UAH 211.8 mio.
Drug prices in
Ukraine are among
lowest in Europe,
CivioFoundation
Researchers of Spanish non-
governmental organization
CivioFoundation have presented
the results of the global
study on drug accessibility.
The organization compared
prices on 14 key drugs in 61
countries using the database of
HealthActionInternational, which
contains drug prices over the
period from 2001 to 2015.
The research concluded Ukraine’s
prices are lowest for almost all
drugs among countries of the
European region. However, the
level of drug accessibility in
Ukraine is among poorest due
to an absence of reimbursement
system in the country. Moreover,
the low-income level of Ukrainians
also makes drugs harder to
access.
REGULATORY UPDATES
Draft Reformation Concept for
Medicinal Products and Medical
Devices Procurements has been
Developed
Ministry of Health published
on its official website the Draft
CMU Resolution “On Approval
of Reformation Concept
for Medicinal Products and
Medical Devices Procurement
Mechanisms” for public
consideration.
The Concept suggests the
implementation of activities aimed
at solving the issues of timely
patients support with qualitative,
safe and efficient medicinal
products, immunobiological
products and medical evices, and
activities aimed at the prevention
of corruption and limited
competition that lead to medicinal
products and medical devices
procurement at an over-inflated
price.
The document authors note
that the Concept designates
the directions, mechanisms and
terms for public procurements
system transformation in
healthcare sector of Ukraine
through the development of
modern convenient system
aimed at the establishment of
competitive environment and
further development of fair
competition in this sector. The
adoption of the Draft Resolution
shall promote the establishment
of professional centralized
procurement organizations in
Ukraine, which requires some
time and incremental actions.
Reimbursement Mechanism of
the Costs of Insulin Products for
Pharmacies
Cabinet of Ministers of Ukraine
Resolution as of 23.03.2016, #
239 “Certain Issues of Insulin
Products Costs Reimbursement”
designates the reimbursement
mechanisms for insulin products
sold by the pharmacies to diabetic
patients within the framework of
pilot project. The reimbursement
of insulin products costs shall be
fulfilled at the rate of reference
price for the medicinal product
approved by the Ministry of
Health of Ukraine.
These medicinal products shall be
sold by prescription only. Diabetic
patients were broken down
into 11 categories. The patients
shall receive their medication
for a lowered price or for free in
accordance with these categories.
The procedure for insulin
products reimbursement foresees
that the pharmacy warehouse
should file monthly report on
the medicinal products sold.
The report should contain
each product’s international
nonproprietary name and trade
Provided by

mark, product’s strength, pack
size, quantity of insulin units per
package, quantity of packages
sold, reference price of full
reimbursement, reference price
of partial reimbursement, name
of healthcare institution, amount
eligible for reimbursement for the
reporting period. Business entity
should submit the relevant report
not later than the 5th day of the
month following the reporting
month, and in December — not
later than the 24th day of the
reporting month. The reports
should be submitted to local
budgets holders who have been
legitimately assigned for the
execution of operating expenses
of local budgets for preferential
provision of insulin products to
diabetic patients defined by the
decisions on such expenditures
in accordance with the legislation
for the reimbursement to
business entity of the amount
stated in the register within 15
days upon the report receipt.
Transition Period for Medical
Devices Trade has been extended
by 01.07.2017
Cabinet of Ministers Resolution
as of march 23, 2016, # 240
“On Amendments to Certain
Resolutions of the Cabinet of
Ministers of Ukraine” has been
published on the official website
of Ukrainian Government.
The Resolution introduces
changes to 3 Technical
Regulations on Medical Devices.
The abovementioned
governmental Resolution
extends the transition period by
01.07.2017. During this period
all medical devices shall be
introduces to the market and
put into operation on the basis
of acting certificate of state
registration.
The compliance assessment
procedures shall become
obligatory starting from July
1, 2017 for registered medical
devices with the unlimited state
registration certificate or with
the certificate expiring after this
date. Registered medical devices
with the certificate expiring after
July 1, 2017, should undergo
the compliance assessment
procedures after the expiration of
such certificate in order to stay
on the market.
Government Initiated the
Extension of Medicinal Products
List Liable for Simplified State
Registration Procedures
On April 20, 2016, Ukrainian
Parliament registered the Draft
Law of Ukraine “On Amendments
to Article 9 of the Law of
Ukraine “On Medicinal Products”
(regarding state registration
(re-registration) of medicinal
products)” (# 4484). The Draft
Law was initiated by the Cabinet
of Ministers of Ukraine and
presented the same say at the
Government session.
The document proposes to
extend the list of medicinal
products liable for simplified
state registration, in particular to
simplify the procedure for those
medicinal products that have
already been registered by the
competent authorities of the USA,
Switzerland, Japan, Australia,
Canada or the European Union.
In addition, the draft proposes to
shorten the term for the Ministry
of Health to make its decision
from one month to 10 business
days.
It is worth to mention that
currently the simplified
registration of medicinal
products that are registered in
the abovementioned countries is
envisaged for those products that
are intended for the treatment of
socially dangerous diseases.
The Parliament Health Care
Committee did not support this
Draft Law and submitted it for
further improvement.
Main Scientific Expert Directorate
also expressed its position
that the simplified registration
procedure is viable to apply only
to those medicinal products,
which substitutes are not
produced in Ukraine.
See all news on regulatory
updates on the Legal Alliance
website.
HEALTHCARE NEWS
The new government intends to
launch state insurance system
The new Cabinet of Minsters
plans to launch the system
of compulsory state medical
insurance as well as voluntary
insurance within healthcare
reformation in the country, the
program of the Cabined states.
The documents say that the
government intends to provide
the accessibility and quality of
primary health care, through
establishing an effective chain of
similar healthcare establishments,
equipping them with modern
diagnostic tools, ensuring the
patient’s possibility of free
choice of a doctor and creation
of mechanisms of financial
motivation for a physician.

Moreover, the Cabinet plans
to create a shared space of
medical institutions of all forms
of ownership and subordination,
implement a common information
space for the collection,
treatment and prognosis of
clinical data, create a single
registry of patients, implement
clinical protocols with the list of
medical services to differentiate
levels of medical aid.
Minister of Healthcare was not
appointed
The new Cabinet of Minister,
which had been approved on
Apr 15, did not provide the
candidacy of the Minister of
Healthcare of Ukraine. The Prime
Minister explained it with failure
to find the appropriate person
it time. However, the search for
the new Head of the MOH is in
the process, while Alexander
Kvitashvili resigned.
On Apr 27, the government
appointed Deputy Minister Viktor
Shafranskiy as acting Minister
of Healthcare. Later on, the
First Deputy Minister Olexandra
Pavlenko was dismissed.
Among the possible key
candidates under consideration
were the member Parliamentary
Committee on Public Health
Konstantyn Yarinich, the Director
of Heart Institute Borys Todurov
and acting Minister of Healthcare
and ex-GM of Novartis Ukraine
Viktor Shafranskiy.
Ukraine failed to implement insulin
reimbursement system since Apr 1
On Apr 1, the launch of the pilot
project on insulin reimbursement
was planned to start. However,
due to unsolved technical issues,
the provision of insulins to
patients did not start.
“The range of technical and
organizational issues should have
been solved,” the Chief freelance
endocrinologist of the MOH Boris
Mankovskiy said. “For example,
in any region of Ukraine the
pharmacy chains, which were to
provide insulin for free and then
to receive compensation from the
state, should have been chosen.”
“To make the legislation work,
few preparatory stages should
be passed; this requires regular
work,” Vice President of the
International Diabetes Association
Natalia Vlasenko said. “Some of
these steps are already passed,
but some issues are still to be
solved.”
Register of insulin-dependent
patients is steadily filling. Digital
prescription was also introduced.
The main issue today is the
selection of pharmacies, which will
provide insulins to a patient on a
preferential basis.
“I am not ready to say when the
system will start working,” Mr.
Mankovskiy noted. “But it is good
that the work is not stopped.”
According to the MOH, as of
01/01/2016, there were 1.22 mio
diabetic patients in Ukraine, over
200 ths of them were insulin-
dependent.
Development of e-Health system in
Ukraine is under discussion
On Apr 27-28, the seminar
on future national strategy on
electronic healthcare system
was held in Kyiv region with the
participation of the World Bank
and the WHO.
e-Health system should become
one of the key components of
healthcare reformation in Ukraine,
the World Bank’s program
manager in healthcare, education
and social protection Fon Zhao.
Implementation of e-Heath
system is a part of the major
project in healthcare, which is
financially supported by the World
Bank.
The project coordinator of the
WHO Bureau Jeraldin Mcqueeney
noted that cooperation with
Ukraine, one of the biggest
countries in Europe, is in priority
and aims to support the reform
process.

Business
Consulting
HR-Consulting
Market
Access
Business
Education
Support of M&A Deals / Pre-investment Due Diligence
Commercial Audit / Business Diagnostics
FCPA Audit / Reputational Audit
Executive Search / Recuiting
Organizational Consulting / Personnel Assessment
Outplacement
Launch Planning / Marketing Analysis & Planning
Regulatory Environment Audit / Business Modelling
Analysis of Prescribers and Consumers
Business Training for Pharmaceutical Companies:
Strategy / Change Management
New Launches / Marketing
UPharma Consulting is a
professional consulting
company, operating in the
Life Sciences sector. We
deliver best global practices
in market knowledge,
people management,
marketing and strategy in
the CIS/CEE.
UPharma Consulting
21st
Marshal Tymoshenko str.,
building 7, office 5
Kiev, 04212
Ukraine
+380 (44) 232 1142
+380 (44) 232 1143
www.upharma-c.com
mailbox@upharma-c.com
Subscribe to
Upharmacia
instantly!

Upharmacia - April 2016

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Viewers also liked

Viewers also liked (10)

Similar to Upharmacia - April 2016

Similar to Upharmacia - April 2016 (19)

More from Eirhub

More from Eirhub (8)

Recently uploaded

Recently uploaded (20)

Upharmacia - April 2016